Clinical Trials · NCT02431325

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

CompletedPhase 2Teduglutide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Massachusetts General Hospital
Enrollment
32
Start date
Dec 2015
Locations
1 site, United States
Primary endpoint
Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake
View Teduglutide compound reference